2020 Biotechnology Awards (Packages) by AI Global Media

Biotechnology Awards 2020

Winners Packages

Alpha Package: £2,995 Exclusive to one winner only! •

Main front cover image and headline on the celebratory magazine

•

Four pages of dedicated content at the front-end of the magazine – approx. 3000 words

•

4 crystal trophies (slate option available at an extra cost)

•

Personalised digital logo

•

Personalised digital certificate

•

2 dedicated pages in any issue of GHP Magazine for 2020

•

Bespoke digital e-brochure – 8 pages and ideal for sending to clients

•

50 hard copies of your bespoke brochure

•

Social media promotion on the GHP social media platforms – provides 1 x Facebook posts (5,000+ followers) and 1 x Twitter (1,500+ followers. 





Jan19216

MMS Holdings

adapts to bring many of its clients the required expertise, drawing on its efforts for well over a decade in the quality and information security space. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards. Operating internationally and supporting a range of clients and service users in such an important market, MMS works hard to remain at the forefront of emerging market developments to ensure excellence at all times. The Regulatory Operations and Compliance Department at MMS completes an extensive, ongoing monthly review of all health authority websites in addition to actively reviewing real-time notifications of regulatory content updates. Once a month, all updated and/or new regulatory content, including guidelines and guidance for industry, is reviewed for relevance. If found pertinent, these updates are then distributed to colleagues within each of the departments for review. The Regulatory and Medical Writing and Safety Risk Management departments at MMS rely on the

MMS Holdings: Most Outstanding Global CRO 2019

Technical Requirements Review Committee to analyze and evaluate the applicability and impact of the latest regulations and requirements on the work the firm undertakes.

Translational Medicine (CTM) at the University of Maryland School and Artificial Intelligence of Pharmacy, to develop the Laboratory aims to significantly Health Analytics Collective. The shorten the approval process for timeline to market a new drug or pharmaceutical and health care medical device, from the point of groups globally. discovery to U.S. Food and Drug Administration approval, can This approach ensures that the The team aims to leverage realstretch to a decade. By pooling firm is able to offer cutting-edge world evidence, observational solutions and support. As a result, Seeking to build upon its current its industry experience and data generated during routine MMS has embraced regulatory technology, a new health research success, recently MMS partnered clinical practice, and patient the supergroup led by the Julia Lab changes globally and invested in with the Julia Lab at MIT, Julia health care databases to augment colleague trainingto and technologytrial within the MIT Computer Science Computing, andregulatory the Center for submission approach complex data and challenges. As part of our overview label claims and/or support new to better support sponsors as its industry evolves. The company has been a pioneer in several key services, forging the way in Policy 0070 and other key transparency initiatives, leadership within organizations such as PhUSE, and plain lay summary programs.

drug applications of this year’s Biotechnology Awards we profile the firm to find out more and explore the with it’s leadingedge software and algorithms secrets behind its phenomenal success. and a depth of regulatory and

Originally established as a data-focused CRO, MMS has maintained its core vision and their values since it’s inception. In its learning management system, MMS has more than 750 trainings that were developed in house. In the past five years, the company has submitted more than 50 brand new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA). The company has offices and colleagues spanning four

continents, with more than 600 full-time colleagues and technical specialists. This started with one woman, Dr. Uma Sharma. Thirteen years ago, what started as a small, oneperson venture has now grown to be a company that’s sized like it has been around for 50 years. Her positivity, visionary leadership, and philosophy on life form the narrative as to why the company has been so successful. Based in Canton, Michigan, which is halfway between the emerging

6 GHP / 2019 Biotechnology Awards

tech hubs of Ann Arbor and Detroit, MMS has used its strategic location to ensure its success from the beginning. When Pfizer closed their doors in Ann Arbor in 2006, Dr. Sharma went from a clinical lead to a consultant, supporting projects for various clients as an individual contributor. She was then quickly approached by former team members enquiring how they could support her efforts, wanting to work for her again. The timing was flawless, and slowly the new team grew. Since then, MMS has grown into a global powerhouse with hundreds of colleagues across North America, Europe, India, and South Africa, using only organic methods. Today, she uses an entrepreneurial mindset to encourage every colleague to “pay it forward” and help the team grow across sites and continents. The closure of the Pfizer site was motivation, and it did not deter her from moving forward doing what she loves – helping to bring life changing therapies to patients worldwide. Working alongside a wide range of clients, MMS now draws on a decade plus experience of various global colleagues to support leading pharmaceutical and biotech companies as well as many smaller enterprises across our

4 GHP / 2019 Biotechnology Awards

MMS Holdings

clinical experience. spectrum of services. A retention To cutthan down the number of rate of greater 93 on percent required trials, globally allows for clinical continuity in the team effectiveness claims expertisecompares and efficiency. for similar drugs in development, examinesmore available evidence from Having completed than 50 existing data, assesses available submissions for drug approval identifies over the treatments, last five years, the firm treatment

MMS Holdings

“This started with one woman, Dr. Uma Sharma. Thirteen years ago, what started as a small, one-person venture has now grown to be a company that’s sized like sciences and with regulatory gaps, and evaluates patient risks. it has been around for submissions. These decisions Then, to process all of these data, the team relies on Julia, an MITincubated programming language designed to solve massive computational problems quickly and accurately, and the use of real-world evidence. This approach is innovative and will help MMS to remain at the forefront of emerging industry developments and to drive positive change in the development of new initiatives and treatments.

include blockchain technology, artificial intelligence, and other

technology platforms; an area visionary leadership, and that the wider healthcare industry must embrace to continue on philosophy on life form pace for the next generation of drug development.

Clinical trial transparency and the company has been so the use of Real World Evidence (RWE) are two key areas where successful.” MMS is set to make a lasting

Thanks to this development and many others, the future looks bright and exciting for MMS. The efforts and proactive decisions that the company is making today will allow it to be at the forefront of delivering strategic new solutions for its clients globally, specifically in the areas of data

contribution to the clinical research community and help the industry utilize their dollars spent in a most efficient manner. At the same time, planned work will continue with more successful projects and submissions of new drugs

to be approved for a multitude of indications. Finally, MMS is at a place where with the combined work of our global colleagues we have made an impact by giving back to the communities which they support – allocating in excess of $250,000 worth of colleague time this past year. MMS and its Founder Dr. Sharma firmly believe that the firm can and will set an example of how a self-sufficient global organization with the right attitude and mindset can forge scientific, technical, and community relationships, bringing joy to its work while at the same time also making a difference in the lives of patients worldwide.

remains a top choice for sponsors who are looking for innovation and demand high quality from their CRO partners. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. Over the years, the firm has embraced regulatory changes globally and invested in colleague training and technology to better support sponsors as our industry evolves. MMS has been a pioneer in several key services, forging the way in Policy 0070 and other key transparency initiatives, leadership within organizations such as PhUSE, and their plain lay summary programs.

Contact Details: Company: MMS Holdings Name: Donald McLean Address: 6880 Commerce Blvd, Canton, MI 48187 USA Telephone Number: 7342450165 Web Address: www.mmsholdings.com

GHP / 2019 Biotechnology Awards 7

Since the beginning, MMS has established and maintained international quality certifications across all sites, allowing us to become leaders as a data CRO. With new regulations in effect, such as the GDPR, MMS easily

GHP / 2019 Biotechnology Awards 5

Company Name Award Title ards 2019 Biotechnolog y Aw

Beta Package: £1,295 • • • • • •

Front cover logo on the celebratory magazine One page of dedicated content - approx. 900 words 1 crystal trophy (slate option available at an extra cost) Personalised digital logo Personalised digital certificate 1 dedicated page in any issue of GHP Magazine for 2020

Feb19025

 Quadsil Inc.

Quadsil Inc. - Best Silicone & Silane R&D Consultancy 2019 - USA leveraging its vast experience in the silicone market. We profile the firm to find out more about

Established in 2001, Quadsil started life as a silicone consulting company by retirees of the Dow Corning Corporation. Together they have a combined 150 years of service experience in silicones, which they draw on to identify potential collaborations and resources to obtain protectable products and technologies. Today, the firm’s clients range from major global industry leaders to new state up firms. Over the

years, Quadsil has expanded its service offering to include the purchase and construction of a water testing analytical lab directed at analyzing drinking water and industrial process waters. The company has also enhanced its partner base to include personnel who share the leadership’s passion for the silicone industry and our continued commitment to being responsible members of their community.

offer cost effective consulting and project development for resource limited start-up companies. Opportunities abound, however, with limited resources it can be difficult, and as such the team then focuses on projects which offer both the best balance of resources and market potential. Looking to the future, Quadsil will be expanding from strictly R&D to also being able to provide process scale-up manufacturing. This will

help the firm as it anticipates increased governmental regulation within the associated fees for compliance. As such, competition with major biotechnology corporations with larger resources will require Quadsil to stay focused, specialized, and form lasting partnerships with its clients to ensure its ongoing success, and enhancing its service offering will help the firm to achieve this and build upon its current success.

Drawing on the team’s vast industry experience, Quadsil strives to

Quadsil TMInc. Contact Details: Company: Quadsil Inc. Name: John Blizzard Address: 210 Arrow Cove, Midland, MI 48642 Telephone Number: 989-496-1434 Web Address: www.quadsil.com

GHP / 2019 Biotechnology Awards 21

Biotechnology Awards 2020

This is to certify that:

Company Name/Logo Have Been Named:

Award Title

CERTIFICATE DATE

Company Name Award Title ards 2019 Biotechnolog y Aw

Gamma Package: £625 • One page of dedicated content – approx. 900 words • 1 crystal trophy (slate option available at an extra cost) • Personalised digital logo

Company Name Award Title ards 2019 Biotechnolog y Aw

Feb19293

 AquiSense Technologies

AquiSense Technologies: Best Provider 2019 - USA Thanks to its patented technology, vast industry experience and global reach, AquiSense this year’s Biotechnology Awards we profile the firm and provide an insight into the driving AquiSense is focused on providing clean water, air, and surfaces without the use of harmful chemicals or hazardous materials. The company offers this through the use of Ultraviolet light in a confined and safe space where the light is only effective to the bacteria in their systems. Other alternatives for disinfection are chemicals which are known to be harmful in unsafe doses or frequent exposure and conventional UV lamps which contain mercury. AquiSense’s expert team has been part of the conventional UV industry for several years and recognized that LEDs are the future of disinfection. While developing its unique products for its valued customers, AquiSense has been able to redefine the UV industry with the smallest UV system in the world. This technology allows for disinfection directly at the point of consumption; something that was previously not a reality. A pioneer in the industry, the firm unveiled the first prototype UV LED system in 2012 and the first commerical product was released in 2015. The company was also the first to release a smallfootprint, embeddable system. AquiSense is the only UV LED provider with continuous

large-scale orders and we have contracts with some of the largest corporations in the world. Beyond its manufacturing and design abilities, the company’s internal research and knowledge unparalleled. AquiSense has the most advanced and longrunning UV LED measured lab in the world that has tested more UV LEDs in a variety of specifications than anyone else.

firm’s product success has to do with installations where disinfection was not previously possible, and looking ahead the firm believes there will be even greater adaptation of its technology as industries and companies come to realise the benefits. Seeking to capitalise on this growth in the UV LED market, AquiSense will continue to enhance its

product offering to build upon its current success. As UV LEDs continue to improve in their light output efficiency and their price drops it will make the evitability of this process even more apparent. AquiSense plans to develop new disinfection products for new markets across the globe as this technology advances to support a wider range of clients over the coming years.

As a result, today the firm works on several projects across the UV LED market, including the BIOWYSE Consortium, a Horizon 2020 project that is studying water disinfection for the International Space Station (ISS). The company also provides its innovative disinfection technology to a sector of the food safety market with the installation of its products in steam ovens to disinfection the steam before it comes in contact with the food. Over recent years the UV industry has been growing rapidly, as it has been involved in large municipality projects, down to residential installations . The real benefit to UV LED products is that no other UV technology can imitate the properties of LEDs. Similar to the shift from tube TVs and monitors to flat screens, the UV disinfection market is seeing a shift from the analog to digital. AquiSense sees UV LED as a creative technology instead of a disruptive. The majority of the

Stage I – GHP Complimentary • Official press release • Inclusion in the SEO online winners’

Contact Details: Company: AquiSense Technologies Name: Oliver Lawal Address: 4400 Olympic Blvd Telephone Number: +1.859.869.4700

GHP / 2019 Biotechnology Awards 23